Turn Therapeutics Inc (TTRX) AI Stock Analysis

• Market Cap: $99.79M
• Dividend Yield: N/A
• Average Volume (3M): 2.86M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 29,788,040
• 10 Day Avg. Volume: 2,856,380
• 30 Day Avg. Volume: 2,856,380
• PEG Ratio: -0.22
• Price to Book (P/B): 11.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.94
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.15
• Price Target Upside: 124.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $3.50 ▲(27.74% Upside)
• Action: Reiterated Date: 04/11/26
• Date: Action: Reiterated 04/11/26

The score is held down primarily by weak financial performance (no revenue, widening 2025 losses, and faster cash burn) and only modest technical setup (below key moving averages with negative MACD). Corporate events provide some support via added financing runway and pipeline/regulatory strengthening, but valuation remains constrained by ongoing losses and no dividend.

Positive Factors

Extended Runway via Growth Capital

Securing an upfront tranche and up-to-$25M facility materially lengthens financing runway, allowing the company to complete the Phase 2 readout and advance registrational planning. This reduces immediate financing pressure and preserves ability to execute clinical milestones that create lasting value.

Negative Factors

Accelerating Cash Burn

The step-up in operating and free cash outflows in 2025 signals increasing funding needs and higher execution risk. Over a 2–6 month horizon this structural trend raises the probability management must draw additional tranches, raise equity, or cut activity, affecting program timelines and dilution outcomes.

Turn Therapeutics Inc Business Overview & Revenue Model

Company Description

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduce...

Read more

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduce...

How the Company Makes Money

null...

Turn Therapeutics Inc Financial Statement Overview

Breakdown	Mar 2026	Dec 2024	Dec 2023
Income Statement
Total Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
EBITDA	-5.81M	-1.75M	-2.26M
Net Income	-3.19M	-1.77M	-2.29M
Balance Sheet
Total Assets	12.16M	2.05M	2.01M
Cash, Cash Equivalents and Short-Term Investments	5.08M	872.60K	1.18M
Total Debt	80.38K	121.04K	25.16K
Total Liabilities	7.48M	2.23M	1.93M
Stockholders Equity	4.69M	-177.43K	85.77K
Cash Flow
Free Cash Flow	-2.72M	-1.46M	-1.42M
Operating Cash Flow	-2.56M	-1.36M	-1.38M
Investing Cash Flow	-152.99K	-99.47K	-44.31K
Financing Cash Flow	6.92M	1.15M	500.00K

Turn Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TTRX	48 Neutral	$99.79M	-16.95	-141.67%	―	―	―
SCNI	44 Neutral	$2.01M	-0.20	―	―	178.82%	-4121.10%
DRMA	44 Neutral	$4.91M	-0.28	-203.36%	―	―	90.53%
PULM	43 Neutral	$4.38M	-2.19	-79.47%	―	-99.97%	35.59%
AZTR	43 Neutral	$3.68M	-0.12	-215.04%	―	-100.00%	93.82%
AIM	41 Neutral	$4.27M	―	212.59%	―	-41.05%	57.35%

Turn Therapeutics Inc Corporate Events